Verition Fund Management
LENZ

Verition Fund Management’s LENZ Therapeutics LENZ Stock Holding History

Verition Fund Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-46,268
Closed -$740K – 3704
2025
Q4 		$740K Buy
+46,268
New +$1.35M ﹤0.01% 2379
2025
Q2 		– Sell
-27,569
Closed -$709K – 3917
2025
Q1 		$709K Buy
+27,569
New +$679K ﹤0.01% 2359
2023
Q3 		– Sell
-32,750
Closed -$596K – 2731
2023
Q2 		$596K Sell
32,750
-55,654
-63% -$1.11M 0.01% 1139
2023
Q1 		$1.52M Buy
+88,404
New +$1.43M 0.02% 796

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Verition Fund Management's LENZ Position: Q1 2026 in Review

Verition Fund Management sold out of LENZ Therapeutics (LENZ) in Q1 2026, closing a stake of 46,268 shares — an estimated $740K sold.

Verition Fund Management first reported a position in LENZ in Q1 2023 and held it in 4 quarters. The position peaked at $1.52M in Q1 2023. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • Verition Fund Management reported no remaining LENZ Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 46,268 LENZ Therapeutics shares in Q1 2026, an estimated $740K.
  • Verition Fund Management first reported a position in LENZ Therapeutics in Q1 2023 and held it in 4 quarters.
  • Verition Fund Management's LENZ Therapeutics position peaked at $1.52M in Q1 2023.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.